Literature DB >> 12971376

Community transmission of extended-spectrum beta-lactamase.

Beatriz Mirelis, Ferran Navarro, Elisenda Miró, Raul Jesús Mesa, Pere Coll, Guillem Prats.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971376      PMCID: PMC3020612          DOI: 10.3201/eid0908.030094

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: The spread of multiresistant gram-negative bacteria in the general population is a problem of paramount importance, but the responsible mechanisms are poorly understood. Several studies have focused on β-lactam resistance in Enterobacteriaceae isolated from stools in healthy people, but they did not specifically investigate the extended-spectrum β-lactamases (ESBL). Furthermore, none of these studies detected ESBL in the evaluated population (,). We performed three survey studies to determine the incidence of Enterobacteriaceae strains producing ESBLs in the stools of outpatients attending our hospital. The first study was performed during a 4-month period (February–May 2001), the second during a 3 month-period (April–June 2002), and the third during 1 month (October 2002). Stool samples were spread onto plates of MacConkey agar containing 2 mg/L of cefotaxime. A colony of each distinct morphotype was analyzed further. Species were identified according to conventional methods (). The susceptibility to β-lactam antibiotics was determined by the disk-diffusion test, following recommendations of the National Committee for Clinical Laboratory Standards (,). The interpretative reading of the antibiogram was performed according to standard guidelines (–). The MICs of cefotaxime and ceftazidime, with and without clavulanic acid, were later determined by E test (AB Biodisk, Solna, Sweden). Strains producing ESBL were defined as strains showing synergism between amoxicillin-clavulanic acid and cefotaxime, ceftazidime, cefepime, or aztreonam (,). All strains suspected of carrying a resistance pattern compatible with hyperproduction of the chromosomal enzymes, as well as resistant strains without synergy, were disregarded. During the first period, 15 (2.1%) of 707 outpatients were carriers of Escherichia coli (14 patients) or Proteus mirabilis (1 patient) with ESBL. This percentage increased during the second period, when 17 (3.8%) of 454 outpatients were carriers of E. coli with ESBL, and again in the third period, when 12 (7.5%) of 160 were carriers of E. coli (11 patients) or Enterobacter cloacae (1 patient) with ESBL. Characterization of the different ESBL isolated during the three study periods is in process. Although Klebsiella pneumoniae carrying ESBL has been detected in our hospital (), as well as in other hospitals in Barcelona (), no ESBL-producing K. pneumoniae strains were identified in this survey. Although we did not disregard either the patients’ previous treatment with antibiotics or previous hospitalization, these patients came to the hospital from the community carrying strains that express ESBL. Moreover, during these three periods we observed a significant increase in the frequency of ESBL carriers (from 2.1% to 7.5%; p<0.005). These data suggest that the community could be a reservoir for these enzymes, as occurs with other microorganisms (–). Many questions remain unanswered regarding the diffusion mechanisms of this resistance in the community. Confirmation of community-based transmission of ESBL would indicate a need for heightened vigilance and further studies to determine the reservoirs and vehicles for dissemination of ESBL within the community.
  8 in total

Review 1.  New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae.

Authors:  A Tomasz
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

2.  Emergence and dissemination of quinolone-resistant Escherichia coli in the community.

Authors:  J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Beta-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain).

Authors:  Montserrat Sabaté; Elisenda Miró; Ferran Navarro; Clara Vergés; Roxana Aliaga; Beatriz Mirelis; Guillermo Prats
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

4.  A between-species comparison of antimicrobial resistance in enterobacteria in fecal flora.

Authors:  M Osterblad; A Hakanen; R Manninen; T Leistevuo; R Peltonen; O Meurman; P Huovinen; P Kotilainen
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].

Authors:  José Ramón Hernández; Alvaro Pascual; Rafael Cantón; Luis Martínez-Martínez
Journal:  Enferm Infecc Microbiol Clin       Date:  2003-02       Impact factor: 1.731

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.

Authors:  Laura Briñas; Myriam Zarazaga; Yolanda Sáenz; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 8.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

  8 in total
  21 in total

1.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.

Authors:  J C Martínez-Pastor; F Vilchez; C Pitart; J M Sierra; A Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-15       Impact factor: 3.267

3.  First detection of a carbapenem-hydrolyzing metalloenzyme in two enterobacteriaceae isolates in Spain.

Authors:  M Teresa Tórtola; Susana Lavilla; Elisenda Miró; Juan José González; Nieves Larrosa; Montserrat Sabaté; Ferran Navarro; Guillermo Prats
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods.

Authors:  F J Castillo García; C Seral García; M Pardos De la Gandara; M I Millán Lou; C Pitart Ferré
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

5.  Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.

Authors:  L Calatayud; M Arnan; J Liñares; M A Dominguez; C Gudiol; J Carratalà; M Batlle; J M Ribera; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

6.  Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.

Authors:  Corinne Arpin; Véronique Dubois; Jeanne Maugein; Jacqueline Jullin; Brigitte Dutilh; Jean-Philippe Brochet; Gilberte Larribet; Isabelle Fischer; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 7.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar.

Authors:  Todisoa Andriatahina; Frédérique Randrianirina; Eliosa Ratsima Hariniana; Antoine Talarmin; Honoré Raobijaona; Yves Buisson; Vincent Richard
Journal:  BMC Infect Dis       Date:  2010-07-12       Impact factor: 3.090

9.  Urinary tract infection in infants caused by extended-spectrum beta-lactamase-producing Escherichia coli: comparison between urban and rural hospitals.

Authors:  Ming-Fang Cheng; Wan-Ling Chen; I-Fei Huang; Jung-Ren Chen; Yee-Hsuan Chiou; Yao-Shen Chen; Susan Shin-Jung Lee; Wan-Yu Hung; Chih-Hsin Hung; Jiun-Ling Wang
Journal:  Pediatr Nephrol       Date:  2016-03-14       Impact factor: 3.714

10.  Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin.

Authors:  Mahbubur Rahman; Shereen Shoma; Harunur Rashid; Shams El Arifeen; A H Baqui; A K Siddique; G B Nair; D A Sack
Journal:  J Health Popul Nutr       Date:  2007-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.